Biosimilars in rheumatology: understanding the rigor of their development

This article examines the current landscape of biosimilar development in rheumatology. As misperceptions about biosimilars exist regarding their comparability to the reference products for clinical use, we review the development paradigm with the goal of improving rheumatologists’ understanding of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Goel, Niti, Chance, Kamali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410928/
https://www.ncbi.nlm.nih.gov/pubmed/27241704
http://dx.doi.org/10.1093/rheumatology/kew206
_version_ 1783232762514243584
author Goel, Niti
Chance, Kamali
author_facet Goel, Niti
Chance, Kamali
author_sort Goel, Niti
collection PubMed
description This article examines the current landscape of biosimilar development in rheumatology. As misperceptions about biosimilars exist regarding their comparability to the reference products for clinical use, we review the development paradigm with the goal of improving rheumatologists’ understanding of the rigor with which biosimilars are developed. With an emphasis on European Union and US markets, it gives an overview of some of the challenges and issues related to biosimilar development that need to be considered by rheumatologists in this increasingly growing therapeutic space.
format Online
Article
Text
id pubmed-5410928
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-54109282017-05-04 Biosimilars in rheumatology: understanding the rigor of their development Goel, Niti Chance, Kamali Rheumatology (Oxford) Reviews This article examines the current landscape of biosimilar development in rheumatology. As misperceptions about biosimilars exist regarding their comparability to the reference products for clinical use, we review the development paradigm with the goal of improving rheumatologists’ understanding of the rigor with which biosimilars are developed. With an emphasis on European Union and US markets, it gives an overview of some of the challenges and issues related to biosimilar development that need to be considered by rheumatologists in this increasingly growing therapeutic space. Oxford University Press 2017-02 2016-05-30 /pmc/articles/PMC5410928/ /pubmed/27241704 http://dx.doi.org/10.1093/rheumatology/kew206 Text en © The Author 2016. Published by Oxford University Press on behalf of the British Society for Rheumatology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Reviews
Goel, Niti
Chance, Kamali
Biosimilars in rheumatology: understanding the rigor of their development
title Biosimilars in rheumatology: understanding the rigor of their development
title_full Biosimilars in rheumatology: understanding the rigor of their development
title_fullStr Biosimilars in rheumatology: understanding the rigor of their development
title_full_unstemmed Biosimilars in rheumatology: understanding the rigor of their development
title_short Biosimilars in rheumatology: understanding the rigor of their development
title_sort biosimilars in rheumatology: understanding the rigor of their development
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410928/
https://www.ncbi.nlm.nih.gov/pubmed/27241704
http://dx.doi.org/10.1093/rheumatology/kew206
work_keys_str_mv AT goelniti biosimilarsinrheumatologyunderstandingtherigoroftheirdevelopment
AT chancekamali biosimilarsinrheumatologyunderstandingtherigoroftheirdevelopment

Ejemplares similares